Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: A prospective study

Neuro-Oncology

Volumn 17, Issue 2, 2015, Pages 289-295

  Morikawa, Aki ^a   Peereboom, David M ^b   Thorsheim, Helen R ^c   Samala, Ramakrishna ^c   Balyan, Rajiv ^c   Murphy, Conleth G ^a   Lockman, Paul R ^c   Simmons, Ahkeem ^a   Weil, Robert J ^b   Tabar, Viviane ^a   Steeg, Patricia S ^d   Smith, Quentin R ^c   Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

blood tumor barrier; brain metastases; breast cancer; capecitabine; lapatinib

Indexed keywords

5' DEOXY 5 FLUOROCYTIDINE; CAPECITABINE; DOXIFLURIDINE; FLUOROURACIL; LAPATINIB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; QUINAZOLINE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CLINICAL ARTICLE; CRANIOTOMY; DRUG BLOOD LEVEL; FEMALE; HUMAN; IC50; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; PROSPECTIVE STUDY; SINGLE DRUG DOSE; STEREOTACTIC RADIOSURGERY; TANDEM MASS SPECTROMETRY; ANALOGS AND DERIVATIVES; BLOOD; BRAIN CHEMISTRY; BRAIN NEOPLASMS; BREAST NEOPLASMS; PATHOLOGY; SECONDARY;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BRAIN CHEMISTRY; BRAIN NEOPLASMS; BREAST NEOPLASMS; CAPECITABINE; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; QUINAZOLINES;

EID: 84922142034     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou141     Document Type: Article

References (32)

1. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22(17):3608-3617.
2. Deeken JF, Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13(6):1663-1674.
3. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000; 18(11):2349-2351.
4. Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007; 18(1):23-28.
5. Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012;29(3):770-781.
6. Lockman PR, Mittapalli RK, Taskar KS, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 2010;16(23):5664-5678.
7. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26(12): 1993-1999.
8. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013; 14(1):64-71.
9. Salvador A, Milllerioux L, Renou A, et al. Simultaneous LC-MS-MS analysis of capecitabine and its metabolites (5′-deoxy-5-fluorocytidine, 5′-deoxy-5-fluorouridine, 5-fluorouracil) after off-line SPE from human plasma. Chromatographia. 2006; 63(11-12):609-615.
10. Polli JW, Olson KL, Chism JP, et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab Dispos. 2009;37(2):439-442.
11. Wan H, Rehngren M, Giordanetto F, et al. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem. 2007;50(19):4606-4615.
12. Uchida Y, Ohtsuki S, Kamiie J, et al. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice. J Pharmacol Exp Ther. 2011;339(2):579-588.
13. Tsukamoto Y, Kato Y, Ura M, et al. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Pharm Res. 2001;18(8):1190-1202.
14. Cohn W. The determination of hemoglobin in tissue extracts or other turbid solutions. J Biol Chem. 1943;1(148):219-223.
15. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34(8): 1274-1281.
16. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet. 2001;40(2):85-104.
17. Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45(4): 291-297.
18. Ekenel M, Hormigo AM, Peak S, et al. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol. 2007;85(2):223-227.
19. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-1459.
20. Burris HA, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005;23(23): 5305-5313.
21. Burris HA, Taylor CW, Jones SF, et al. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res. 2009;15(21):6702-6708.
22. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001;1(2):85-94.
23. Polli JW, Humphreys JE, Harmon KA, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008;36(4):695-701.
24. Chien AJ, Auerback G, Rugo HS, et al. A phase I dose-escalation study of 5-day intermittent oral lapatinib therapy with biomarker anlaysis in patients with HER-2-overexpressing breast cancer. J Clin Onc. 2014;32(14):1472-1479.
25. Grommes C, Oxnard GR, Kris MG, et al. 'Pulsatile' high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011;13(12):1364-1369.
26. EGFR inhibition using high dose administration of erlotinib weekly for recurrent malignant gliomas with EGFR variant III mutation NCT01257594. National Library of Medicine, Bethesda, MD, USA. Available at http://clinicaltrials.gov. Accessed February 1, 2014.
27. Vivanco I, Robins HI, Rohle D, et al. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012;2(5):458-471.
28. Durmus S, Sparidans RW, Wagenaar E, et al. Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm. 2012; 9(11):3236-3245.
29. Tang SC, Lagas JS, Lankheet NA, et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer. 2012; 130(1):223-233.
30. Stewart DJ, Mikhael NZ, Nair RC, et al. Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol. 1988;11(2): 152-158.
31. Lien EA, Wester K, Lonning PE, et al. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer. 1991;63(4):641-645.
32. Boogerd W, Tjahja IS, van de Sandt MM, et al. Penetration of idarubicin into malignant brain tumor tissue. J Neurooncol. 1999;44(1):65-69.